Antiretroviral Prices in 2023

HIV/AIDS

Download

Copyright: Stefan Heunis

MSF Access Campaign has documented and published the prices of antiretroviral (ARV) medicines for treating people living with HIV/AIDS since 2001 in order to create more transparency about, and help increase access to, ARV medicines. In this publication, we compile the sources and prices of ARV medicines in 2023.

Read, watch, share

Technical brief |

04 September 2024

HIV/AIDS

Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit

Research article |

16 August 2024

HIV/AIDS

Antiretroviral Prices in 2023

Read, watch, share

Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit

Lancet HIV: The long wait for long-acting HIV prevention and treatment formulations

Lancet Global Health: Paving the way for affordable and equitable liposomal amphotericin B access worldwide

Pharmaceutical corporation ViiV must urgently supply HIV drug CAB-LA according to global public health needs

Activists at AIDS2024 Demand: Break Gilead’s Lenacapavir Monopoly Gilead’s Price 100,000% Higher than Target Generic Price for 100% Effective Prevention Shot

Ghana: National AIDS Control Programme letter to Danaher to reduce the price of GeneXpert test

Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)